State of the Art: Concise ReviewClinicopathologic Features of Advanced Squamous NSCLC
Keywords
Cited by (0)
Disclosure: Mark A. Socinski has acted as a consultant/advisor to Eli Lilly and Company. Paul Bunn has received personal fees from Lilly, AstraZeneca, Bristol-Myers Squibb, Daiichi Sankyo, Eisai, Merck, Roche Genentech, Novartis, Pfizer, and Clovis. David Gandara has acted as a consultant/advisor to Lilly and Merck. Fred R. Hirsch has acted as a consultant/advisor to Bristol-Myers Squibb, Lilly, Pfizer, Merck, Ventana, and Roche/Genentech, and he has received research funding from Bristol-Myers Squibb, Amgen, and Lilly/Imclone. Corey J. Langer has received honoraria from and acted as a consultant/advisor to Lilly and Roche/Genentech. Carlos Mayo is a former employee of Lilly and a current employee of Merck. Silvia Novello has participated in speakers’ bureaus for Boehringer Ingelheim, Merck, AstraZeneca, Bristol-Myers Squibb, and Roche. Coleman Obasaju is an employee of Lilly. Luis Paz-Ares has received personal fees from AstraZeneca, Bristol-Myers Squibb, Clovis, Lilly, Roche, Novartis, Merck, Clovis Oncology, Amgen, and Pfizer. Maurice Pérol has acted as a consultant/advisor to AstraZeneca, Boehringer Ingelheim, Lilly, and Roche, and he has received nonfinancial support from Roche. Suresh S. Ramalingam has acted as a consultant/advisor to Amgen, AbbVie, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Genentech, Lilly, and Novartis. Martin Reck has acted as a consultant/advisor to and participated in speakers’ bureaus for AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Lilly, Merck, MSD, Pfizer, F. Hoffmann-La Roche, and Celgene. Craig H. Reynolds has received personal fees from Lilly, Genentech, Boehringer Ingelheim, AstraZeneca, and Celgene. Thomas E. Stinchcombe has acted as a consultant/advisor to Lilly Oncology. Nick Thatcher has received personal fees from Amgen, Celgene, Oncogenix, AstraZeneca, Roche Genentech, and Otsuka and acted as a consultant/advisor to Lilly. Heather Wakelee has acted as a consultant/advisor to Novartis, ACEA, Pfizer, and Peregrine and has received research funding from AstraZeneca, Bristol-Myers Squibb, Celgene, Lilly, MedImmune, Novartis, Pfizer, Roche Genentech, Gilead, and Xcovery. The remaining authors declare no conflict of interest.